Opaleye Management Inc. Crinetics Pharmaceuticals, Inc. Transaction History

Opaleye Management Inc.

$390 Million
Q2 2024

20 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$34.76 - $46.81 $3.39 Million - $4.56 Million	-97,500 Reduced 31.71%	210,000 $9.83 Million
Q4 2023 Feb 14, 2024	SELL	$25.62 - $37.07 $1.6 Million - $2.32 Million	-62,500 Reduced 16.89%	307,500 $10.9 Million
Q3 2023 Nov 14, 2023	SELL	$15.97 - $30.59 $7.59 Million - $14.5 Million	-475,000 Reduced 56.21%	370,000 $11 Million
Q2 2023 Aug 14, 2023	BUY	$15.73 - $23.6 $931,310 - $1.4 Million	59,206 Added 7.53%	845,000 $15.2 Million
Q1 2023 May 12, 2023	BUY	$15.31 - $21.1 $823,586 - $1.14 Million	53,794 Added 7.35%	785,794 $12.6 Million
Q4 2022 Feb 10, 2023	BUY	$15.49 - $19.05 $940,243 - $1.16 Million	60,700 Added 9.04%	732,000 $13.4 Million
Q2 2022 Aug 15, 2022	SELL	$16.49 - $27.64 $357,832 - $599,788	-21,700 Reduced 3.13%	671,300 $12.5 Million
Q1 2022 May 16, 2022	SELL	$17.15 - $28.31 $538,510 - $888,934	-31,400 Reduced 4.33%	693,000 $15.2 Million
Q4 2021 Feb 14, 2022	BUY	$19.35 - $28.41 $6.24 Million - $9.16 Million	322,287 Added 80.15%	724,400 $20.6 Million
Q3 2021 Nov 16, 2021	BUY	$16.88 - $25.23 $3.4 Million - $5.09 Million	201,613 Added 100.56%	402,113 $8.46 Million
Q2 2021 Aug 16, 2021	BUY	$15.9 - $21.15 $198,750 - $264,375	12,500 Added 6.65%	200,500 $3.78 Million
Q1 2021 May 18, 2021	BUY	$13.3 - $17.55 $2.5 Million - $3.3 Million	188,000 New	188,000 $2.87 Million
Q4 2020 Feb 12, 2021	SELL	$12.08 - $17.46 $2.9 Million - $4.19 Million	-240,000 Closed	0 $0
Q3 2020 Nov 16, 2020	SELL	$13.62 - $17.66 $2.66 Million - $3.45 Million	-195,200 Reduced 44.85%	240,000 $3.76 Million
Q2 2020 Aug 14, 2020	BUY	$13.04 - $23.23 $866,508 - $1.54 Million	66,450 Added 18.02%	435,200 $7.63 Million
Q1 2020 May 15, 2020	BUY	$11.52 - $26.46 $1.18 Million - $2.72 Million	102,650 Added 38.58%	368,750 $5.42 Million
Q4 2019 Feb 14, 2020	BUY	$15.24 - $25.09 $900,684 - $1.48 Million	59,100 Added 28.55%	266,100 $6.68 Million
Q3 2019 Nov 14, 2019	BUY	$14.91 - $25.01 $2.55 Million - $4.28 Million	171,000 Added 475.0%	207,000 $3.11 Million
Q2 2019 Aug 14, 2019	SELL	$21.48 - $27.71 $794,760 - $1.03 Million	-37,000 Reduced 50.68%	36,000 $900,000
Q1 2019 May 15, 2019	BUY	$21.07 - $29.31 $1.54 Million - $2.14 Million	73,000 New	73,000 $1.66 Million

Others Institutions Holding CRNX

# of Institutions

244

Shares Held

78.2M

Call Options Held

268K

Put Options Held

197K

Black Rock Inc. New York, NY

6.23M
Shares

$314 Million
0.01% of portfolio
Driehaus Capital Management LLC Chicago, IL

6.11M
Shares

$308 Million
2.95% of portfolio
Wellington Management Group LLP Boston, MA

4.62M
Shares

$233 Million
0.04% of portfolio
Vanguard Group Inc Valley Forge, PA

4.51M
Shares

$227 Million
0.0% of portfolio
Price T Rowe Associates Inc Baltimore, MD

4.41M
Shares

$222 Million
0.02% of portfolio

View Full List

About Crinetics Pharmaceuticals, Inc.

Ticker CRNX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 53,752,800
Market Cap $2.71B
Description
Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III ...

More about CRNX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Opaleye Management Inc., based on Form 13F filings with the SEC.

News

Stay updated on Opaleye Management Inc. with notifications on news.

Account